Floatz logo

Tirelizumab

Head and Neck Squamous Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

129 Active assets in the Head and Neck Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Epirubicin
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
Docetaxel
National Cancer Institute (NCI)
Phase 3B
Cetuximab
Fate Therapeutics
Phase 3B

View all 50 →

Same molecule, other indications

Tirelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
62 / 100
View asset →
Oral CancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →